Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy
Terminated · Phase 2 · NCT03640481
Conditions: Chronic Graft-versus-host-disease
At a glance
- Research payments reported, 2025
- $13,750
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 159
About the trial
- Sponsor
- Kadmon, a Sanofi Company
- Tested
- Belumosudil (KD025) (drug)
- Dates
- Started 2018-10-11; completion 2023-12-11
- Results posted
- Yes
This is a Phase 2, randomized, multicenter study to evaluate the efficacy and safety of KD025 in subjects with Chronic Graft Versus Host Disease (cGVHD) after at least 2 prior lines of systemic therapy
From ClinicalTrials.gov, last updated 2024-12-12. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi-aventis U.S. LLC reported $13,750 in research payments for this study in 2025 (11 payments).
Products named: Rezurock
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $13,750
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.